Skip to the notes
KLOW Prescribed Notes

Sources to keep nearby

The sources beside these KLOW peptide notes

Here’s the reading behind the pages. I’ve kept a short note beside each source so you can see what it tested and why its findings don’t automatically belong to KLOW.

Hair research, with the ingredient named

Ingredient studies answering other questions

FDA sources on identity, safety and status

  • FDA’s TB-500 review, 2026

    Distinguishes TB-500 from full-length thymosin beta-4 and reports finding no published study giving TB-500 to people. It also discusses missing safety information and limits in batch testing.

  • FDA’s BPC-157 review, 2026

    Discusses limited safety evidence and possible immune reactions. Those concerns aren’t measured rates of harm from KLOW.

  • FDA’s KPV review, 2026

    Describes missing basic safety tests and possible immune reactions. It doesn’t establish a blend safety record.

  • FDA’s bulk-substance safety page

    Current as of April 22, 2026. The relevant ingredients appear as “nominated but withdrawn,” with GHK-Cu limited to injectable routes. Taking back a nomination isn’t clearance.

  • FDA’s questions and answers about compounding

    Explains why a compounded medicine is not FDA-approved, even when it has a prescription.